Brain Cancer @ Leeds

Professor Alan Melcher – Group Leader

alan
Contact Information

Professor Alan Melcher
Professor of Clinical Oncology and Biotherapy
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St James’s University Hospital
LS9 7TF, Leeds
United Kingdom

tel: +44 (0) 113 8436
email: a.a.melcher@leeds.ac.uk

Overview

I graduated in medicine from the University of Oxford in 1989, and trained in Clinical Oncology (radiotherapy and chemotherapy) in Cardiff, London and Leeds. Following completion of my PhD in London, I was a post-doctoral research fellow at the Mayo Clinic, Minnesota, before returning to the UK, where I am currently Professor of Clinical Oncology and Biotherapy in Leeds. I combine a clinical practice in melanoma, with laboratory and early clinical trial research focused on oncolytic viruses (OV) for the treatment of cancer.

Specifically, our preclinical and translational programme is focused on whether tumour cells can provide appropriate antigens for priming of anti-tumour immunity, and whether oncolytic viral therapy can trigger immunogenic tumour cell death. We have shown in both murine and human systems that both innate and adaptive immune priming are critical components of oncolytic virotherapy.

We have also found that OV can be genetically engineered to express a cDNA library derived from normal or tumour tissue, to generate a potent anti-cancer vaccine. Moreover, this virally expressed epitope library can be used to identify key combinations of novel antigens for optimal anti-tumour immune priming. In patients, we focus on proof of concept trials, for example administering intravenous reovirus before planned surgery to resect colorectal cancer metastatic to the liver.

In this study, by analyzing tissue after the operation, we were able to show that replicating virus was delivered selectively to malignant, but not normal, tissue. Despite the presence of anti-reovirus neutralizing antibodies (NAB) in the circulation, peripheral blood mononuclear cells, granulocytes and platelets were all able to ‘hitch-hike’ and protect reovirus in the blood, allowing its delivery to tumour. Further such trials, using other viruses for other cancers, are now in development in parallel with iterative ‘bench to bedside and back again’ research.

Publications

Donnelly OG Measles causes immunogenic death in human melanoma In: International Oncolytic virus conference .

Hennig IM; Naik JD; Brown S; Szubert AJ; Anthoney DA; Jackson DP; Melcher AA; Crawford M; Bradley C; Brown MB; Seymour MT Severe sequence-specific toxicity when capecitabine is given. Journal of Clinical Oncology, , pp. 0-0.

Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA (2013) Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer, .

Tai LH; Zhang J; Scott KJ; Tanese de Souza C; Alkayyal AA; Abhirami Ananth A; Sahi S; Adair RA; Bakur Mahmoud A; Sad S; Bell JC; Makrigiannis AP; Melcher AA; Auer R (2013) Perioperative influenza vaccination reduces post-operative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res, .

Donnelly O; Harrington K; Melcher A; Pandha H (2013) Live viruses to treat cancer. J R Soc Med, .

Boisgerault N; Kottke T; Thompson J; Diaz RM; Rommelfanger-Konkol D; Embry A; Saenz D; Poeschla E; Pulido J; Vile R; Pandha H; Harrington K; Melcher A; Selby P (2013) Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Molecular Therapy, .

Kottke T; Donnelly O; Boisgerault N; Diaz R; Rommelfanger-Konkol D; Pulido J; Thompson J; Mukhopadhyay D; Knutson K; Behrens M; Kaspar R; Coffey M; Selby P; Harrington K; Melcher A; Pandha H; Vile R (2013) Tumor Relapse Is Associated with an Innate Immune Resistant Phenotype across Tumor and Treatment Types Which Can Be Targeted with Rational Second Line Therapies , pp. S249-S249.

Boisgerault N; Pulido J; Kottke T; Donnelly O; Celis E; Thompson J; Diaz R; Harrington K; Pandha H; Selby P; Melcher A; Vile R (2013) Tumor Recurrences Share Immunogenic Antigens across Both Tumor Types and Primary Treatments Which Can Be Therapeutically Targeted with VSV-cDNA Libraries , pp. S152-S152.

Kottke T; Donnelly O; Ilett E; Thompson J; Diaz R; Coffey M; Selby P; Pandha H; Harrington K; Melcher A; Vile R (2013) In Vivo Expansion of a Recipient Population of Cell Carriers Allows for Highly Effective Systemic Delivery of Oncolytic Reovirus Even in the Presence of Neutralizing Antibody , pp. S7-S7.

Diaz R; Rommelfanger-Konkol D; Kottke T; Thompson J; Donnelly O; Embry A; Melcher A; Vile R (2013) Novel VSV-Based Immunotherapy for Brain Tumors , pp. S195-S195.

Adair RA; Scott KJ; Fraser S; Errington-Mais F; Pandha H; Coffey M; Selby P; Cook GP; Vile R; Harrington KJ; Toogood G; Melcher AA (2013) Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer, 132 (10), pp. 2327-2338.

Melcher A (2013) Oncolytic viruses for cancer therapy , pp. A12-A13.

Kyula JN; Khan AA; Mansfield D; Karapanagiotou EM; McLaughlin M; Roulstone V; Zaidi S; Pencavel T; Touchefeu Y; Seth R; Harrington KJ; Chen NG; Yu YA; Zhang Q; Szalay AA; Melcher AA; Vile RG; Pandha HS; Ajaz M (2013) Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, .

Rommelfanger DM; Grau MC; Diaz RM; Ilett E; Thompson JM; Kottke TJ; Vile RG; Alvarez-Vallina L; Melcher A (2013) The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering tlr agonists to oncolytic virus-treated mice. Molecular Therapy, 21 (2), pp. 348-357.

Donnelly OG; Errington-Mais F; Steele L; Hadac E; Jennings V; Scott K; Peach H; Phillips RM; Bond J; Pandha H; Harrington K; Vile R; Russell S; Selby P; Melcher AA (2013) Measles virus causes immunogenic cell death in human melanoma. Gene Ther, 20 (1), pp. 7-15.

Kyula JN; Roulstone V; Karapanagiotou EM; Harrington KJ; Melcher AA (2012) Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opinion on Biological Therapy, 12 (12), pp. 1669-1678.

Nuovo GJ; Garofalo M; Valeri N; Volinia S; Roulstone V; Harrington KJ; Melcher A; Adair R; Scott K; Rose A; Toogood G; Cohn DE; Phelps M; Vile R; Galanis E; Sehl S; Coffey MC (2012) Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 25 (10), pp. 1333-1344.

Rommelfanger DM; Grau MC; Diaz RM; Ilett E; Vile RG; Alvarez-Vallina L; Melcher A; Thompson JM; Kottke TJ (2012) The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice. Molecular Therapy, .

Orchard-Webb D; Fox N; Elghazawy RM; Speirs V; Smith AM; Lodge JPA; Melcher AA; Verbeke CS; Blair GE (2012) Development of a Chimaeric Oncolytic Adenovirus Vector for Pancreatic Cancer Biotherapy , pp. S18-S18.

Roulstone V; Twigger K; Zaidi S; Pencavel T; Kyula JN; White C; McLaughlin M; Seth R; Karapanagiotou EM; Mansfield D; Harrington KJ; Coffey M; Nuovo G; Vile RG; Pandha HS; Melcher AA (2012) Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Therapy, .

Donnelly O; Vile R; Pandha H; Harrington K; Melcher A (2012) The hitchhiker’s guide to virotherapy. Oncotarget, 3 (8), pp. 735-736.

Donnelly OG; Melcher AA; Vile RG; Pulido J (2012) What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?. Immunotherapy, 4 (8), pp. 749-751.

Dunlop MG; Farrington SM; Tenesa A; Ooi L-Y; Smillie C; Grimes G; Semple C; Prendergast J; Ballereau S; Zgaga L; Campbell H; Dobbins SE; Whiffin N; Broderick P; Henrion M; Frampton M; Ma YP; Olver B; Penegar S; Lubbe S; Lloyd A; Vijayakrishnan J; Houlston RS; Jones AM; Palles C; Spain S; Domingo E; Martin L; Gorman M; Barclay E; Cazier J-B; Carvajal-Carmona LG; Tomlinson IP; Chander I; Rudan I; Theodoratou E; Starr JM; Deary I; Kirac I; Kovacevia D; Aaltonen LA; Renkonen-Sinisalo L; Mecklin J-P; Matsuda K; Nakamura Y; Okada Y; Gallinger S; Duggan DJ; Conti D; Schumacher F; Casey G; Newcomb P; Hopper J; Jenkins MA; Easton D; Shah M; Pharoah P; Edler D; Janson M; Lindblom A; Liu T; Smith CG; West H; Cheadle JP; Midgley R; Kerr DJ; Thomas H; Maher E; Evans G; Walker L; Halliday D; Lucassen A; Paterson J; Hodgson S; Homfray T; Side L; Izatt L; Donaldson A; Tomkins S; Morrison P; Brewer C; Henderson A; Davidson R; Murday V; Cook J; Haites N; Bishop T; Sheridan E; Green A; Marks C; Carpenter S; Broughton M; Greenhalge L; Suri M; Lenander C; Dalén J; Hjern F; Lundqvist N; Lindforss U; Påhlman L; Smedh K; Törnqvist A; Holm J; Andersson M; Ekelund S; Olsson L; MacDonald G; Samuel LM; Ahmad A; Corrie P; Jodrell D; Palmer C; Wilson C; O’Hagan J; Smith D; McDermott R; Walshe J; Cassidy J; McDonald A; Mohammed N; White J; Yosef H; Waterston A; Breathnach O; Grogan L; Thomas R; Wilson R; Eatock M; Henry P; Houston R; Johnston P; Geh I; Danwata F; Hindley A; Susnerwala S; Bradley C; Conn A; Raine A; Twelves C; Falk S; Hopkins K; Tahir S; Dhadda A; Maraveyas A; Sgouros J; Teo M; Ahmad R; Cleator S; Creak A; Lowdell C; Riddle P; Benstead K; Farrugia D; Reed N; Shepherd S; Stout R; Levine E; Mullamitha S; Wilson G; Saunders M; Valle J; Jones A; Weaver A; Clark PI; Haylock B; Iqbal MI; Myint AS; Beesley S; Sevitt T; Nicoll J; Daniel F; Ford V; Talbot T; Butt M; Hamid A; MacK P; Roy R; Osborne R; McKinna F; Alsab H; Basu D; Murray P; Sizer B; Gollins S; Azam FA; Neupane R; Glaholm J; Blesing C; Lowndes S; Medisetti A; Gaya A; Leslie M; Maisey N; Ross P; Dunn G; Wasan HS; Al-Salihi O; Tan LT; Dent J; Hofmann U; Joffe JK; Sherwin E; Soomal R; Chakrabarti A; Joseph S; Van Der Voet J; Wadd NJ; Wilson D; Anjarwalia S; Hall J; Hughes R; Polychronis A; Scarffe JH; Hill M; James RD; Shah R; Summers J; Hartley A; Carney D; McCaffrey J; Bystricky B; O’Reilly S; Gupta R; Al-Mishlab T; Gidden F; O’Hara R; Stewart J; Ashford R; Glynne-Jones R; Harrison M; Mawdsley S; Barlow H; Tighe M; Walther J; Neal J; Rees C; Bridgewater J; Karp S; McGovern U; Atherton PJ; El-Deeb H; MacMillan C; Patel K; Bessell EM; Dickinson PD; Potter V; Jephcott C; McAdam K; Wrigley J; Muthuramalingam S; O’Callaghan A; Melcher L; Braconi C; Geh JI; Palmer D; Narayana P; Steven N; Rudman S; Chakraborti P; Kelly K; MacGregor C; Whillis D; Freebairn A; Gildersleve J; Sharif S; Astras G; Hickish T; Beech D; Ellis R; Kulkarni R; Shankland K; Begent R; Mayer A; Meyer T; Strauss S; Hall V; Raj S; Chau I; Cunningham D; Birtle A; Biswas A; Wise M; Cummins S; Essapen S; Middleton G; Topham C; Langley R; Webb A; Wilkins M; Iveson TJ; Askill C; Wagstaff J; Azzabi A; Bateman A; Prejbisz J; Tsang D; Ali N; O’Neill P; Cottrill C; Propper D; Lofts FJ; Kennedy J; Anthoney DA; Cooper R; Crellin A; Melcher A; Seymour M; Baughan C; Alexander E; Crown J; Fennelly D; Adab F; Giridharan S; Pedley I; Wright K; Bliss P; Cogill G; Lo N; Toy E; Hochhauser D; Ledermann J; Brewster A; Maughan T; Mort D; Mukherjee S; Adams R; Madi A; Pope M; Mason M; Maughen T; Griffiths G; Dobrowsky W; Calvert P; Leonard G; Ford H; Moody AM; Goriah S; Clive S; Dawson L; McLean C; Phillips HA; Gopi K; Tomlinson M; Clenton S; Furniss D; Hornbuckle J; Pledge S; Wadsley J; Abbas M; Marshall E; Harper-Wynne C; Barnes A; Kumar S; Vigneswaran V; Genton M; Sparrow G; Bale C; Fuller C; Mullard A; Stuart N; Williams R; Keane M; Hodgkinson E; Rogers P; Kaplan R; Meade A; Kenny S; Fisher D; Harper L; Mitchell J; Nichols L; Sydes B; Clement L; Kay E; Courtney C; Gallagher M; Murphy C; Thompson L; Beall S; Hassan S; Gracie R; Parmar M; Parker C; Rudd R; Johnson P; Whelan J; Northover J; Brown J; Aapro M (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44 (7), pp. 770-776.

Dave R; Errington-Mais F; Kim D; Toogood G; Melcher A (2012) VIRAL WARFARE: FRONT LINE DEFENCE AND ARMING THE IMMUNE SYSTEM: THE USE OF AN ONCOLYTIC VIRUS AS A VACCINE AGAINST COLORECTAL LIVER METASTASES. GUT, 61 , pp. A24-A25.

Donnelly OG; Errington-Mais F; Prestwich R; Harrington K; Pandha H; Vile R; Melcher AA (2012) Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol, 13 (9), pp. 1834-1841.

Dunlop MG; Dobbins SE; Farrington SM; Jones AM; Palles C; Whiffin N; Tenesa A; Spain S; Broderick P; Ooi LY; Domingo E; Smillie C; Henrion M; Frampton M; Martin L; Grimes G; Gorman M; Semple C; Ma YP; Barclay E; Prendergast J; Cazier JB; Olver B; Penegar S; Lubbe S; Chander I; Carvajal-Carmona LG; Ballereau S; Lloyd A; Vijayakrishnan J; Zgaga L; Rudan I; Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium; Starr JM; Deary I; Kirac I; Kovacević D; Aaltonen LA; Renkonen-Sinisalo L; Mecklin JP; Matsuda K; Nakamura Y; Okada Y; Gallinger S; Duggan DJ; Conti D; Newcomb P; Hopper J; Jenkins MA; Schumacher F; Casey G; Easton D; Shah M; Pharoah P; Lindblom A; Liu T; Swedish Low-Risk Colorectal Cancer Study Group; Smith CG; West H; Cheadle JP; COIN Collaborative Group; Midgley R; Kerr DJ; Campbell H; Tomlinson IP; Houlston RS (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet, 44 (7), pp. 770-776.

Nuovo GJ; Garofalo M; Valeri N; Volinia S; Roulstone V; Harrington KJ; Melcher A; Adair R; Scott K; Rose A; Toogood G; Roulstone V; Harrington KJ; Melcher A; Adair R; Scott K; Rose A; Toogood G; Cohn DE; Phelps M; Vile R; Galanis E; Sehl S; Coffey MC (2012) Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, .

Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA (2012) Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med, 4 (138), pp. 138ra77.

Turrell SJ; Macnab SA; Rose A; Melcher AA; Whitehouse A (2012) A Herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures. Int J Oncol, 40 (6), pp. 2081-2089.

Kottke T; Donnelly O; Boisgerault N; Diaz R; Thompson J; Chester J; Pandha H; Harrington K; Melcher A; Vile R (2012) Characterization of the Mechanisms of Tumor Dormancy and Recurrence Following Front Line Immuno-, Viro- or Suicide Gene-, Therapy , pp. S268-S268.

Rommelfanger D; Boisgerault N; Diaz R; Donnelly O; Kottke T; Thompson J; Melcher A; Vile R (2012) Improving the Efficacy of Adoptive T Cell Therapy by Combination with Viro-/Immuno-/Radio-Therapy , pp. S209-S209.

Kottke T; Pulido J; Embry A; Thompson J; Diaz R; Rommelfanger D; Ilett E; Selby P; Melcher A; Vile R (2012) VSV-Expressed cDNA Libraries Cure Established Melanoma and Identify Repertoires of Antigens Which Co-Operate To Stimulate Protective Tumor Immunity , pp. S260-S260.

Kottke T; Thompson J; Ilett E; Selby P; Melcher A; Vile R (2012) The Broad Antigenic Repertoire Provided by a VSV-cDNA Vaccine Forces Tumor Escape Variants into a Reproducible, and Predictable, Phenotype Which Is Highly Sensitive to Second Line Chemotherapy , pp. S129-S129.

Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res, 18 (7), pp. 2080-2089.

Pulido J; Kottke T; Thompson J; Galivo F; Wongthida P; Diaz RM; Rommelfanger D; Ilett E; Pease L; Pandha H; Harrington K; Selby P; Melcher A; Vile R (2012) Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. NATURE BIOTECHNOLOGY, 30 (4), pp. 336-343.

Simpson GR; Horvath A; Annels NE; Metcalf S; Pandha HS; Pencavel T; Seth R; Peschard P; Harrington KJ; Price T; Coffin RS; Mostafid H; Melcher AA (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer, 106 (3), pp. 496-507.

Win SJ; McMillan DG; Errington-Mais F; Ward VK; Young SL; Baird MA; Melcher AA (2012) Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br J Cancer, 106 (1), pp. 92-98.

Hall K; Scott KJ; Rose A; Desborough M; Harrington K; Pandha H; Parrish C; Vile R; Coffey M; Bowen D; Errington-Mais F; Melcher AA (2012) Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Biores Open Access, 1 (1), pp. 3-15.

Mansfield D; Pencavel T; Kyula JN; Zaidi S; Roulstone V; Karapanagiotou L; Khan AA; McLaughlin M; Touchefeu Y; Seth R; Harrington KJ; Thway K; Melcher AA; Vile RG; Pandha HS (2012) Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncology, .

Dave R; West E; Toogood G; Kirn D; Melcher A (2012) Viral warfare: Front line defence and arming the immune system: The use of an oncolytic virus as a vaccine against colorectal liver metastases , pp. 29-30.

Twigger K; Roulstone V; Kyula J; Karapanagiotou EM; Syrigos KN; Morgan R; White C; Bhide S; Nuovo G; Coffey M; Thompson B; Jebar A; Errington F; Melcher AA; Vile RG; Pandha HS; Harrington KJ (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12 , pp. 368.

Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R (2011) Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther, 22 (11), pp. 1343-1353.

Vile R; Melcher A (2011) An intravenous stimulus package for oncolytic virotherapy. Mol Ther, 19 (11), pp. 1930-1932.

Kottke T; Chester J; Ilett E; Thompson J; Diaz R; Coffey M; Selby P; Nuovo G; Pulido J; Mukhopadhyay D; Pandha H; Harrington K; Melcher A; Vile R (2011) Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther, 19 (10), pp. 1802-1812.

West EJ; Scott KJ; Jennings VA; Melcher AA (2011) Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. Br J Cancer, 105 (6), pp. 787-795.

Kottke T; Errington F; Pulido J; Galivo F; Thompson J; Wongthida P; Diaz RM; Chong H; Ilett E; Chester J; Pandha H; Harrington K; Selby P; Melcher A; Vile R (2011) Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med, 17 (7), pp. 854-859.

Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC CANCER, 11 .

Melcher A; Parato K; Bell JC; Rooney CM (2011) Thunder and lightning: Immunotherapy and oncolytic viruses collide. Molecular Therapy, 19 (6), pp. 1008-1016.

Melcher A; Parato K; Rooney CM; Bell JC (2011) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther, 19 (6), pp. 1008-1016.

Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA (2011) Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res, 17 (9), pp. 2767-2776.

Ochoa MC; Hervas-Stubbs S; Palazon A; Martinez-Forero I; Berraondo P; Sarobe P; Melero I; Melcher A (2011) International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010. Cancer Immunology, Immunotherapy, 60 (5), pp. 753-756.

Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R (2011) Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. MOL THER, 19 (1), pp. 140-149.

Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R (2011) VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling. MOL THER, 19 (1), pp. 150-158.

Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP (2011) Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One, 6 (9), pp. e22842.

Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A (2011) Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer, 10 , pp. 20.

Wilson EB; El-Jawhari J; Jennings VA; Hall GD; Melcher AA; Meade JL; Cook GP (2010) Tumour microenvironment associated modulation of natural killer cells by TGF-beta , pp. 171-171.

Heinemann L; Simpson GR; Annels NE; Vile R; Melcher A; Prestwich R; Harrington KJ; Pandha HS (2010) The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis. MOL THER, 18 (12), pp. 2085-2093.

Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS (2010) REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res, 16 (22), pp. 5564-5572.

Adair RA; Merrick AE; Selby PJ; Melcher AA; Toogood GJ (2010) Reovirus activates human innate immune cell killing of colorectal cancer. BRITISH JOURNAL OF SURGERY, 97 , pp. 27-27.

Kottke T; Pulido J; Thompson J; Harrington K; Selby P; Melcher A; Vile R (2010) Tumour Immune Evasion Enforced by Viral cDNA Library Vaccination Can Be Exploited for Ambush of Emerging Tumour Cell Variants , pp. 1415-1415.

Hingorani M; White CL; Zaidi S; Pandha HS; Melcher AA; Bhide SA; Nutting CM; Syrigos KN; Vile RG; Vassaux G; Harrington KJ (2010) Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair. MOL THER, 18 (9), pp. 1599-1605.

Pencavel T; Seth R; Hayes A; Melcher A; Pandha H; Vile R; Harrington KJ (2010) Locoregional intravascular viral therapy of cancer: precision guidance for Paris’s arrow?. Gene Ther, 17 (8), pp. 949-960.

Harrington KJ; Karapanagiotou EM; Roulstone V; Twigger KR; White CL; Vidal L; Beirne D; Prestwich R; Newbold K; Ahmed M; Thway K; Nutting CM; Coffey M; Harris D; Vile RG; Pandha HS; Debono JS; Melcher AA (2010) Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res, 16 (11), pp. 3067-3077.

Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Pulido J; Pavelko K; Pease L; Melcher A; Vile R (2010) Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res, 70 (11), pp. 4539-4549.

Kottke T; Hall G; Pulido J; Diaz RM; Thompson J; Chong H; Selby P; Coffey M; Pandha H; Chester J; Melcher A; Harrington K; Vile R (2010) Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J CLIN INVEST, 120 (5), pp. 1551-1560.

Desborough M; Errington-Mais F; Melcher A (2010) Oncolytic reovirus as a treatment for AML , pp. 72-72.

Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS (2010) Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev, 21 (2-3), pp. 91-98.

Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG (2010) Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther, 21 (4), pp. 439-450.

John J; Ismail M; Riley C; Askham J; Morgan R; Melcher A; Pandha H (2010) Differential effects of Paclitaxel on dendritic cell function. BMC IMMUNOL, 11 .

Ilett EJ; Prestwich RJ; Melcher AA (2010) The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther, 10 (3), pp. 369-379.

Hingorani M; Spitzweg C; Vassaux G; Newbold K; Melcher A; Pandha H; Vile R; Harrington K (2010) The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery. CURR CANCER DRUG TAR, 10 (2), pp. 242-267.

Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R (2010) Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. GENE THER, 17 (2), pp. 158-170.

Merrick AE; Ilett EJ; Melcher AA (2009) JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs, 10 (12), pp. 1372-1382.

Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA (2009) Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol, 183 (7), pp. 4312-4321.

Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R (2009) Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res, 15 (19), pp. 6158-6166.

Kottke T; Pulido J; Thompson J; Sanchez-Perez L; Chong H; Calderwood SK; Selby P; Harrington K; Strome SE; Melcher A; Vile RG (2009) Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res, 69 (19), pp. 7767-7774.

Prestwich RJ; Errington F; Diaz RM; Pandha HS; Harrington KJ; Melcher AA; Vile RG (2009) The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther, 20 (10), pp. 1119-1132.

Willmon C; Harrington K; Kottke T; Prestwich R; Melcher A; Vile R (2009) Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy. MOL THER, 17 (10), pp. 1667-1676.

Hatfield P; Hingorani M; Radhakrishna G; Cooper R; Melcher A; Crellin A; Kwok-Williams M; Sebag-Montefiore D (2009) Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol, 92 (2), pp. 210-214.

Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res, 15 (13), pp. 4374-4381.

Pandha H; Melcher A; Harrington K; Vile R (2009) Oncolytic Viruses: Time to Compare, Contrast, and Combine?. MOL THER, 17 (6), pp. 934-935.

Karapanagiotou E; Pandha HS; Hall G; Chester J; Melcher A; Coffey M; de Bono J; Gore ME; Nutting CM; Harrington KJ (2009) Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers .

Saunders M; Anthoney A; Coffey M; Mettinger K; Thompson B; Melcher A; Nutting CM; Harrington K (2009) Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers .

Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA (2009) Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. GENE THER, 16 (5), pp. 689-699.

Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile RG (2009) Therapeutic Efficacy of Oncolytic VSV Virotherapy in an Immune Competent Host: Relative Contributions of Viral Replication, Innate and Adaptive Immune Reactivity , pp. S94-S94.

Ilett E; Prestwich R; Kottke T; Thompson J; Willmon C; Coffey M; Selby P; Harrington K; Melcher A; Vile RG (2009) Cell Carrier-Mediated Protection Allows for Systemic Delivery of Oncolytic Viruses in Virus-Immune Hosts , pp. S300-S300.

Kottke T; Pulido J; Thompson J; Sanchez-Perez L; Chong H; Calderwood SK; Dong HD; Pease L; Selby P; Harrington K; Melcher A; Vile RG (2009) Inflammatory Killing of the Pancreas Induces Multiple Immune Checkpoints Which Protect from Autoimmunity but Which Can Be Manipulated To Achieve Anti Tumor Immunity , pp. S154-S154.

Kottke T; Thompson J; Diaz RM; Pulido J; Willmon C; Coffey M; Selby P; Melcher A; Harrington K; Vile RG (2009) Targeting the Tumor Vasculature To Enhance Systemic Delivery of Oncolytic Viruses , pp. S158-S158.

Prestwich RJ; Scott KJ; Brown J; Harnden P; Whelan P; Cartledge J; O’Donnell D; Pandha HS; Selby PJ; Banks RE; Merrick AE; Melcher AA (2009) The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int, 103 (6), pp. 740-746.

Kottke T; Thompson J; Diaz RM; Pulido J; Willmon C; Coffey M; Selby P; Melcher A; Harrington K; Vile RG (2009) Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. CLIN CANCER RES, 15 (2), pp. 561-569.

West E; Morgan R; Scott K; Merrick A; Lubenko A; Pawson D; Selby P; Hatfield P; Prestwich R; Fraser S; Eves D; Anthoney A; Twelves C; Beirne D; Patel P; O’Donnell D; Watt S; Waller M; Dietz A; Robinson P; Melcher A (2009) Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother, 32 (1), pp. 66-78.

Agrawal VK; Copeland KM; Barbachano Y; Rahim A; Seth R; White CL; Hingorani M; Nutting CM; Kelly M; Harris P; Pandha H; Melcher AA; Vile RG; Porter C; Harrington KJ (2009) Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. GENE THER, 16 (1), pp. 78-92.

Pandha H; Melcher A; Vile R; Harrington K (2009) 5th international meeting on replicating oncolytic virus therapeutics Banff, Alberta, Canada, 18-22 March 2009. Molecular Therapy, 17 (6), pp. 934-935.

Hingorani M; White CL; Merron A; Peerlinck I; Gore ME; Slade A; Scott SD; Nutting CM; Pandha HS; Melcher AA; Vile RG; Vassaux G; Harrington KJ (2008) Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. CANCER RES, 68 (23), pp. 9771-9778.

Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG (2008) Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer. MOL THER, 16 (12), pp. 1910-1918.

Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res, 14 (22), pp. 7358-7366.

Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS (2008) A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. CLIN CANCER RES, 14 (21), pp. 7127-7137.

Heinemann L; Kottke T; Vile R; Coffey MC; Harrington K; Melcher A; Pandha HS (2008) Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model , pp. 951-952.

Karapanagiotou E; Pandha H; Hall G; Chester J; Melcher A; De Bono J; Gore M; Nutting C; Harrington K (2008) Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers , pp. 952-952.

Kottke T; Thompson J; Diaz RM; Pulido J; Willmon C; Coffey M; Selby P; Melcher A; Harrington K; Vile R (2008) Systemic delivery of oncolytic vectors to treat metastatic disease , pp. 1063-1063.

Heinemann L; Simpson G; Harrington K; Melcher A; Coffey MC; Pandha HS (2008) Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model , pp. 99-99.

Prestwich RJ; Harrington KJ; Pandha HS; Vile RG; Melcher AA; Errington F (2008) Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther, 8 (10), pp. 1581-1588.

Prestwich R; Vile R; Melcher A (2008) Cancer immunotherapy. NEW ENGL J MED, 359 (10), pp. 1072-1072.

Hill KS; Errington F; Steele LP; Merrick A; Morgan R; Selby PJ; Georgopoulos NT; O’Donnell DM; Melcher AA (2008) OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol, 181 (5), pp. 3108-3115.

Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA (2008) Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther, 15 (18), pp. 1257-1270.

Hatfield P; Merrick AE; West E; O’Donnell D; Selby P; Vile R; Melcher AA (2008) Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J IMMUNOTHER, 31 (7), pp. 620-632.

Comins C; Heinemann L; Harrington K; Melcher A; De Bono J; Pandha H (2008) Reovirus: Viral therapy for cancer ‘as nature intended’. CLIN ONCOL-UK, 20 (7), pp. 548-554.

Hingorani M; White CL; Zaidi S; Merron A; Peerlinck I; Gore ME; Nutting CM; Pandha HS; Melcher AA; Vile RG; Vassaux G; Harrington KJ (2008) Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: Implications for sodium iodide symporter gene therapy. CLIN CANCER RES, 14 (15), pp. 4915-4924.

Harrington KJ; Melcher A; Vassaux G; Pandha HS; Vile RG (2008) Exploiting synergies between radiation and oncolytic viruses. CURR OPIN MOL THER, 10 (4), pp. 362-370.

Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT (2008) Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. , pp. 3411-3417.

Prestwich RJ; Harrington KJ; Vile RG; Melcher AA (2008) Immunotherapeutic potential of oncolytic virotherapy. LANCET ONCOL, 9 (7), pp. 610-612.

Kottke T; Galivo F; Wongthida P; Diaz RM; Thompson J; Jevremovic D; Barber GN; Hall G; Chester J; Selby P; Harrington K; Melcher A; Vile RG (2008) Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. MOL THER, 16 (7), pp. 1217-1226.

White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. GENE THER, 15 (12), pp. 911-920.

Merrick A; Diaz RM; O’Donnell D; Selby P; Vile R; Melcher A (2008) Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother, 57 (6), pp. 897-906.

Errington F; Steele L; Prestwich R; Harrington KJ; Pandha HS; Vidal L; de Bono J; Selby P; Coffey M; Vile R; Melcher A (2008) Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol, 180 (9), pp. 6018-6026.

Qiao J; Wang H; Kottke T; Diaz R; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG (2008) Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. GENE THER, 15 (8), pp. 604-616.

White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ (2008) Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. GENE THER, 15 (6), pp. 424-433.

Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA (2008) The immune system–is it relevant to cancer development, progression and treatment?. Clin Oncol (R Coll Radiol), 20 (2), pp. 101-112.

Twigger K; Vidal L; White CL; De Bono JS; Bhide S; Coffey M; Thompson B; Vile RG; Heinemann L; Pandha HS; Errington F; Melcher AA; Harrington KJ (2008) Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. CLIN CANCER RES, 14 (3), pp. 912-923.

Prestwich RJD; Errington-Mais F; Harrington KJ; Pandha HS; Selby PJ; Melcher AA (2008) Oncolytic viruses: do they have a role in anti-cancer therapy?. Clinical Medicine: Oncology, , pp. 83-96.

Bonney GK; Craven RA; Prasad R; Melcher AF; Selby PJ; Banks RE (2008) Circulating markers of biliary malignancy: opportunities in proteomics?. Lancet Oncol, 9 (2), pp. 149-158.

Qiao J; Wang HX; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K (2008) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. CLIN CANCER RES, 14 (1), pp. 259-269.

Qiao J; Kottke T; Willmon C; Galivo F; Wongthida P; Diaz RM; Thompson J; Ryno P; Barber GN; Chester J; Selby P; Harrington K; Melcher A; Vile RG (2008) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. NAT MED, 14 (1), pp. 37-44.

Kottke T; Sanchez-Perez L; Diaz RM; Thompson J; Chong H; Harrington K; Calderwood SK; Pulido J; Georgopoulos N; Selby P; Melcher A; Vile R (2007) Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. CANCER RES, 67 (24), pp. 11970-11979.

White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ (2007) Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Therapy, , pp. 0-0.

Qiao J; Kottke T; Willmon C; Galivo F; Wongthida P; Diaz RM; Thompson J; Ryno P; Barber G; Chester JD; Selby PJ; Harrington K; Melcher AA; Vile RG (2007) Purging Metastases in Lymphoid Organs Using a Combination of Antigen-non Specific Adoptive T Cell Therapy, Oncolytic Virotherapy, and Immunotherapy. Nature Medicine, , pp. 0-0.

Harris D; Vidal L; Melcher A; Newbold K; Anthony A; Karavasilis V; Agarwal R; White C; Twigger K; Coffey M; Mettinger K; Thompson B; Pandha H; De-Bono J; Harrington K (2007) A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. MOL CANCER THER, 6 (12), pp. 3458S-3458S.

Craven I; Crellin A; Cooper R; Melcher A; Byrne P; Sebag-Montefiore D (2007) Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer, 97 (10), pp. 1333-1337.

Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik JD; Chester JD; Selby PJ; Harrington K; Melcher AA; Vile RG (2007) Loading of Oncolytic Vesicular Stomatitis Virus onto Antigen Specific T Cells Enhances the Efficacy of Adoptive T Cell Therapy of Tumors. Gene Therapy, , pp. 0-0.

Errington-Mais F; Twigger KR; Kottke T; Thompson J; Steele LP; Ilett E; Prestwich RJD; Pandha HS; Coffey M; Selby PJ; Vile RG; Harrington KJ; White CL; Melcher AA (2007) Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma. Gene Therapy, , pp. 0-0.

Georgopoulos NT; Merrick A; Scott N; Selby PJ; Melcher A; Trejdosiewicz LK (2007) CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer, 121 (6), pp. 1373-1381.

Hill KSK; Errington-Mais F; Georgopoulos NT; Steele LP; Selby PJ; Melcher AA; O’Donnell DM (2007) Ok432-Activated Human Dendritic Cells Kill Tumour Cells Via Cd40/Cd40 Ligand Interactions. Blood, , pp. 0-0.

Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A (2007) Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res, 13 (15 Pt 1), pp. 4487-4494.

Fraser S; Merrick A; Errington F; Selby P; Toogood G; Melcher A (2007) Reovirus as a potentially immunogenic as well as cytotoxic therapy for metastatic colorectal cancer , pp. 1049-1049.

O’Connell M; Mortimer PS; Melcher A; Layton AM (2007) Diagnosis and management of cutaneous side-effects in patients receiving treatment based on epidermal growth factor blockade , pp. 3-3.

Hingorani M; White CL; Agrawal VK; Vidal L; Melcher A; Harrington KJ (2007) Combining radiation and cancer gene therapy: A potential marriage of physical and biological targeting?. CURR CANCER DRUG TAR, 7 (4), pp. 389-409.

Perry SE; Robinson P; Melcher A; Quirke P; Bühring HJ; Cook GP; Blair GE (2007) Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett, 581 (6), pp. 1137-1142.

Sanchez-Perez L; Kottke T; Daniels GA; Diaz RM; Thompson J; Pulido J; Melcher A; Vile RG (2006) Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J IMMUNOL, 177 (6), pp. 4168-4177.

Harrop R; Hawkins R; Anthoney A; Steven N; Habib N; Griffiths R; Melcher A; Wassan H; Naylor S (2006) Open label phase II studies of modified vaccinia ankara expressing the tumor antigen 5T4 given in conjunction with IFL and FOLFOX chemotherapy regimens: Final analysis of safety and immunogenicity of MVA 5T4 given before, during and after chemotherapy. , pp. 106S-106S.

Errington-Mais F; Bateman A; Kottke T; Thompson J; Harrington KJ; Hatfield P; Selby PJ; Vile RG; Melcher AA (2006) Allogeneic Tumor Cells Expressing Fusogenic Membrane Glycoproteins as a Platform for Clinical Cancer Immunotherapy. Clinical Cancer Research, 12 (4), pp. 1333-1341.

Errington F; Jones J; Merrick A; Bateman A; Harrington K; Gough M; O’Donnell D; Selby P; Vile R; Melcher A (2006) Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther, 13 (2), pp. 138-149.

Hatfield P; Merrick AE; O’Donnell DM; Selby PJ; Vile RG; West EJ; Melcher AA (2006) Optimisation of Dendiritic Cell Loading with Tumour Cell Lysates for Cancer Immunotherapy. Clinical Cancer Research, , pp. 0-0.

Ilett L; Errington F; Morgan R; Vile R; Selby P; Melcher A (2006) Dendritic cell activation by tumor cell-derived exosomes. , pp. S149-S150.

Merrick A; Diaz R; Vile R; Melcher A (2006) Peptide-pulsed dendritic cell vaccines; Autologous or allogeneic dendritic cells? , pp. S151-S151.

Vidal L; Twigger K; White C; Coffey M; Thompson B; De-Bono J; Pandha HS; Melcher A; Kaye S; Harrington KJ (2005) Reovirus enhances radiation cytotoxicity in vitro and in vivo. , pp. 9005S-9006S.

Drury N; Shingler W; Chikoti P; Redchenko I; Kelleher M; Hawkins R; Anthoney A; Steven N; Habib N; Griffiths R; Melcher A; Wasan H; Nicholls J; Naylor S; Carroll M; Kingsman S; Harrop R (2005) Phase II studies of MVA expressing the tumour antigen 5T4 given with 5-FU based chemotherapies: safety, immunogenicity and clinical responses. IMMUNOLOGY, 116 , pp. 34-34.

Aldouri A; Merrick A; Prasad R; Melcher A; Toogood G (2005) Vaccination against colorectal cancer: a comparison of turnout lysate preparations from liver metastases , pp. 1309-1309.

John J; Dalgleish AG; Melcher AA; Pandha HS (2005) Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination. Journal of Immunological Methods, 299 , pp. 37-46.

Merrick A; Errington F; Milward K; O’Donnell D; Harrington K; Bateman A; Pandha H; Vile R; Morrison E; Selby P; Melcher A (2005) Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer, 92 (8), pp. 1450-1458.

Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher AA; Holmen S; Daniels GA; Vile RG (2005) Potent Selection of Antigen Loss Variants of B16 Melanoma Following Inflammatory Killing of Melanocytes In vivo. Cancer Research, 65 (5), pp. 2009-2017.

Hatfield P; Merrick AE; Harrington KJ; Vile RG; Bateman A; Selby PJ; Melcher AA (2005) Radiation Induced Cell Death and Dendritic Cells- Potential for Cancer Immunotherapy?. Clinical Oncology, 17 (1), pp. 1-11.

Daniels GA; Sanchez-Perez L; Diaz RM; Kottke T; Thompson J; Lai M; Gough MJ; Karim M; Bushell A; Chong H; Melcher AA; Harrington KJ; Vile RG (2004) A simple method to cure established tumors by inflammatory killing of normal cells. Nature Biotechnology, 22 (9), pp. 1125-1132.

Perry SE; Cook GP; Melcher AA; Quirke P; Blair GE (2004) Defining potential targets for cell-based immunotherapy of colorectal cancer In: British Cancer Research Meeting 2004 , pp. S65-S65.

Gough MJ; Melcher AA; Crittenden MR; Sanchez-Perez L; Voellmy R; Vile RG (2004) Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. GENE THER, 11 (13), pp. 1099-1104.

Daniels G; Sanchez-Perez L; Kottke T; Diaz RM; Thompson J; Lai M; Gough M; Karim M; Bushell A; Chong H; Melcher A; Harrington K; Vile RG (2004) Intentional killing of normal nelanocytes by gene transfer generates curative anti melanoma immunity without obligate autoimmunity , pp. S134-S135.

Todyrk S; Eaton J; Birchall L; Greenhalgh R; Soars D; Dalgleish AG; Melcher AA; Pandha HS (2004) Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunology, Immunotherapy, 53 (4), pp. 323-330.

Casey DG; Lysaght J; James T; Bateman A; Melcher AA; Todryk SM (2003) Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine. IMMUNOLOGY, 110 (1), pp. 105-111.

Phan V; Errington-Mais F; Cheong C; Kottke T; Gough M; Altmann S; Brandenburger A; Emery S; Strome S; Bateman A; Bonnotte B; Melcher AA; Vile RG (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nature Medicine, 9 (9), pp. 1215-1219.

Melcher AA; Sebag-Montefiore D (2003) Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. BRIT J CANCER, 88 (9), pp. 1352-1357.

Phan V; Neczyporenko F; Bonnotte B; Linardakis E; Thompson J; Melcher A; Vile R (2003) Neuroblastoma cell vaccines expressing Vesicular Stomatitis Virus G protein are highly immunogenic in vivo , pp. S125-S125.

Olivier K; Kottke T; Bateman A; Harrington K; Linardakis E; Ahmed A; Gough M; Riddle D; Peterson T; Simari R; Melcher A; Vile R (2003) Fusing tumor cell vaccines are potent immunogens at least in part through the release of exosome-like vesicles which load dendritic cells with tumor antigen , pp. S276-S276.

Phan V; Errington F; Cheong SC; Kottke T; Gough M; Altmann S; Brandenburger A; Emery S; Bateman A; Melcher A; Vile R (2003) A novel genetic method to generate and isolate small, short lived but highly potent dendritic cell tumor cell hybrid vaccines , pp. S271-S271.

Linardakis E; Bateman AR; Phan V; Ahmed A; Gough MJ; Olivier K; Kennedy R; Errington-Mais F; Harrington KJ; Melcher AA; Vile RG (2002) Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion. Cancer Research, 62 (19), pp. 5495-5504.

Harrington KJ; Melcher AA; Bateman AR; Ahmed A; Vile RG (2002) Cancer gene therapy: Part 2. Candidate transgenes and their clinical development. CLIN ONCOL-UK, 14 (2), pp. 148-169.

Harrington KJ; Bateman AR; Melcher AA; Ahmed A; Vile RG (2002) Cancer gene therapy: Part 1. Vector development and regulation of gene expression. CLIN ONCOL-UK, 14 (1), pp. 3-16.

Bateman AR; Harrington KJ; Kottke T; Ahmed A; Melcher AA; Gough MJ; Linardakis E; Riddle DS; Dietz A; Lohse CM; Strome S; Peterson T; Simari RD; Vile RG (2002) Viral fusogenic membrane glycoproteins kill solid tumour cells by non apoptotic mechanisms that promote cross presentation of tumour antigens by dendritic cells. Cancer Research, 62 (22), pp. 6566-6578.

Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK (2002) Lack of specificity of cell surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. Journal of Gene Medicine, 4 , pp. 592-600.

Melcher AA; Bateman AR; Harrington KJ; Ahmed A; Gough MJ; Vile RG (2002) Dendritic cells for the immunotherapy of cancer. Clinical Oncology, 14 (3), pp. 185-192.

Gough MJ; Melcher AA; Ahmed A; Crittenden MR; Riddle DS; Linardakis E; Ruchatz AN; Emiliusen LM; Vile RG (2001) Macrophages orchestrate the immune response to tumor cell death. CANCER RES, 61 (19), pp. 7240-7247.

Melcher A; Brammer C; Sebag-Montefiore D (2001) Radical chemoradiation for squamous cell carcinoma of the anus using a two phase technique with no boost. BRIT J CANCER, 85 , pp. 103-103.

Melcher AA (2001) Chemoradiation: From the Laboratory to the Clinic. Clinical Oncology, 13 (5), pp. 356-360.

Todyrk S; Melcher AA; Bottley G; Gough MJ; Vile RG (2001) Cell death associated with genetic prodrug activation therapy of colorectal cancer. Cancer Letters, 174 (1), pp. 25-33.

© Copyright Leeds 2017